{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:05:01Z","timestamp":1788822301475,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T00:00:00Z","timestamp":1546473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T00:00:00Z","timestamp":1546473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"a Grant-in-Aid for Scientific Research","award":["16K09382"],"award-info":[{"award-number":["16K09382"]}]},{"name":"a Grant from the Smoking Research Foundation","award":["P-14"],"award-info":[{"award-number":["P-14"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.1007\/s12072-018-9921-7","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T07:09:11Z","timestamp":1546499351000},"page":"248-252","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Liver damage related to immune checkpoint inhibitors"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9111-5668","authenticated-orcid":false,"given":"Naoshi","family":"Nishida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,3]]},"reference":[{"issue":"Suppl 1","key":"9921_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000451015","volume":"92","author":"N Nishida","year":"2017","unstructured":"Nishida N, Kudo M. Immunological microenvironment of hepatocellular carcinoma and its clinical implication. Oncology 2017;92(Suppl 1):40\u201349","journal-title":"Oncology"},{"key":"9921_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000449342","volume":"6","author":"M Kudo","year":"2016","unstructured":"Kudo M. Immune checkpoint blockade in hepatocellular carcinoma: 2017 update. Liver Cancer 2016;6:1\u201312","journal-title":"Liver Cancer"},{"key":"9921_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000462153","volume":"6","author":"M Kudo","year":"2017","unstructured":"Kudo M. A new era of systemic therapy for hepatocellular carcinoma with regorafenib and lenvatinib. Liver Cancer 2017;6:177\u2013184","journal-title":"Liver Cancer"},{"key":"9921_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000484619","volume":"7","author":"M Kudo","year":"2018","unstructured":"Kudo M. Management of hepatocellular carcinoma in Japan as a world-leading model. Liver Cancer 2018;7:134\u2013147","journal-title":"Liver Cancer"},{"issue":"Suppl 1","key":"9921_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000451016","volume":"92","author":"M Kudo","year":"2017","unstructured":"Kudo M. Immune checkpoint inhibition in hepatocellular carcinoma: basics and ongoing clinical trials. Oncology 2017;92(Suppl 1):50\u201362","journal-title":"Oncology"},{"key":"9921_CR6","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1159\/000480258","volume":"35","author":"N Nishida","year":"2017","unstructured":"Nishida N, Kudo M. Role of immune checkpoint blockade in the treatment for human hepatocellular carcinoma. Dig Dis 2017;35:618\u2013622","journal-title":"Dig Dis"},{"key":"9921_CR7","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2016;2:1346\u20131353","journal-title":"JAMA Oncol"},{"key":"9921_CR8","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1097\/COC.0000000000000374","volume":"41","author":"BM Huffman","year":"2018","unstructured":"Huffman BM, Kottschade LA, Kamath PS, Markovic SN. Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management. Am J Clin Oncol 2018;41:760\u2013765","journal-title":"Am J Clin Oncol"},{"key":"9921_CR9","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1001\/jama.2018.13995","volume":"320","author":"DB Johnson","year":"2018","unstructured":"Johnson DB, Chandra S, Sosman JA. Immune checkpoint inhibitor toxicity in 2018. JAMA 2018;320:1702\u20131703","journal-title":"JAMA"},{"key":"9921_CR10","doi-asserted-by":"publisher","first-page":"220","DOI":"10.21037\/jgo.2017.08.14","volume":"9","author":"A Sanjeevaiah","year":"2018","unstructured":"Sanjeevaiah A, Kerr T, Beg MS. Approach and management of checkpoint inhibitor-related immune hepatitis. J Gastrointest Oncol 2018;9:220\u2013224","journal-title":"J Gastrointest Oncol"},{"issue":"Suppl 1","key":"9921_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000481246","volume":"93","author":"N Nishida","year":"2017","unstructured":"Nishida N, Kudo M. Oncogenic signal and tumor microenvironment in hepatocellular carcinoma. Oncology 2017;93(Suppl 1):160\u2013164","journal-title":"Oncology"},{"key":"9921_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000486487","volume":"7","author":"M Kudo","year":"2018","unstructured":"Kudo M. Combination cancer immunotherapy in hepatocellular carcinoma. Liver Cancer 2018;7:20\u201327","journal-title":"Liver Cancer"},{"key":"9921_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jtho.2018.09.001","volume":"14","author":"JJ Lin","year":"2019","unstructured":"Lin JJ, Chin E, Yeap BY, Ferris LA, Kamesan V, Lennes IT, et al. Brief report: Increased hepatotoxicity associated with sequential immune checkpoint inhibitor and crizotinib therapy in patients with non-small-cell lung cancer. J Thorac Oncol 2019;14:135\u2013140","journal-title":"J Thorac Oncol"},{"key":"9921_CR14","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","volume":"31","author":"Y Zen","year":"2018","unstructured":"Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol 2018;31:965\u2013973","journal-title":"Mod Pathol"},{"key":"9921_CR15","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.2147\/DDDT.S115493","volume":"10","author":"X Zhang","year":"2016","unstructured":"Zhang X, Ran Y, Wang K, Zhu Y, Li J. Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis. Drug Des Dev Ther 2016;10:3153\u20133161","journal-title":"Drug Des Dev Ther"},{"key":"9921_CR16","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/ijc.30678","volume":"141","author":"W Wang","year":"2017","unstructured":"Wang W, Lie P, Guo M, He J. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data. Int J Cancer 2017;141:1018\u20131028","journal-title":"Int J Cancer"},{"key":"9921_CR17","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/liv.13746","volume":"38","author":"DL Suzman","year":"2018","unstructured":"Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int 2018;38:976\u2013987","journal-title":"Liver Int"},{"key":"9921_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23\u201334","journal-title":"N Engl J Med"},{"key":"9921_CR19","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521\u20132532","journal-title":"N Engl J Med"},{"key":"9921_CR20","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017;377:1824\u20131835","journal-title":"N Engl J Med"},{"key":"9921_CR21","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1056\/NEJMc1302338","volume":"368","author":"A Ribas","year":"2013","unstructured":"Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013;368:1365\u20131366","journal-title":"N Engl J Med"},{"key":"9921_CR22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122\u2013133","journal-title":"N Engl J Med"},{"key":"9921_CR23","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017;377:1345\u20131356","journal-title":"N Engl J Med"},{"key":"9921_CR24","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s00535-016-1263-4","volume":"52","author":"K Ikeda","year":"2017","unstructured":"Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 2017;52:512\u2013519","journal-title":"J Gastroenterol"},{"key":"9921_CR25","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00535-016-1247-4","volume":"52","author":"M Kudo","year":"2017","unstructured":"Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. J Gastroenterol 2017;52:494\u2013503","journal-title":"J Gastroenterol"},{"key":"9921_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317\u2013370","journal-title":"Hepatol Int"},{"key":"9921_CR27","doi-asserted-by":"publisher","first-page":"E367","DOI":"10.3390\/cancers10100367","volume":"10","author":"N Nishida","year":"2018","unstructured":"Nishida N, Nishimura T, Kaido T, Minaga K, Yamao K, Kamata K, et al. Molecular scoring of hepatocellular carcinoma for predicting metastatic recurrence and requirements of systemic chemotherapy. Cancers (Basel) 2018;10:E367","journal-title":"Cancers (Basel)"},{"key":"9921_CR28","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 2017;389:2492\u20132502","journal-title":"Lancet"},{"key":"9921_CR29","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940\u2013952","journal-title":"Lancet Oncol"},{"key":"9921_CR30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","volume":"59","author":"B Sangro","year":"2013","unstructured":"Sangro B, Gomez-Martin C, de la Mata M, Inarrairaegui M, Garralda E, Barrera P, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81\u201388","journal-title":"J Hepatol"},{"key":"9921_CR31","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","volume":"68","author":"E De Martin","year":"2018","unstructured":"De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 2018;68:1181\u20131190","journal-title":"J Hepatol"},{"key":"9921_CR32","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41424-018-0049-9","volume":"9","author":"HG Reddy","year":"2018","unstructured":"Reddy HG, Schneider BJ, Tai AW. Immune checkpoint inhibitor-associated colits and hepatitis. Clin Transl Gastroenterol 2018;9:180","journal-title":"Clin Transl Gastroenterol"},{"key":"9921_CR33","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1055\/s-0038-1667358","volume":"38","author":"BA Nadeau","year":"2018","unstructured":"Nadeau BA, Fecher LA, Owens SR, Razumilava N. Liver toxicity with cancer checkpoint inhibitor therapy. Semin Liver Dis 2018;38:366\u2013378","journal-title":"Semin Liver Dis"},{"key":"9921_CR34","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jhep.2016.11.015","volume":"66","author":"M Ziemer","year":"2017","unstructured":"Ziemer M, Koukoulioti E, Beyer S, Simon JC, Berg T. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Hepatol 2017;66:657\u2013659","journal-title":"J Hepatol"},{"key":"9921_CR35","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1097\/TXD.0000000000000814","volume":"4","author":"D Gassmann","year":"2018","unstructured":"Gassmann D, Weiler S, Mertens JC, Reiner CS, Vrugt B, Nageli M, et al. Liver allograft failure after nivolumab treatment-a case report with systematic literature research. Transpl Direct 2018;4:e376","journal-title":"Transpl Direct"},{"key":"9921_CR36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/CMR.0000000000000410","volume":"28","author":"JC Kuo","year":"2018","unstructured":"Kuo JC, Lilly LB, Hogg D. Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review. Melanoma Res 2018;28:61\u201364","journal-title":"Melanoma Res"},{"key":"9921_CR37","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/annonc\/mdx548","volume":"29","author":"P Biondani","year":"2018","unstructured":"Biondani P, De Martin E, Samuel D. Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient. Ann Oncol 2018;29:286\u2013287","journal-title":"Ann Oncol"},{"key":"9921_CR38","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/jclinpath-2018-205143","volume":"71","author":"DM Karamchandani","year":"2018","unstructured":"Karamchandani DM, Chetty R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists\u2019 perspective. J Clin Pathol 2018;71:665\u2013671","journal-title":"J Clin Pathol"},{"key":"9921_CR39","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.2217\/imt-2016-0057","volume":"8","author":"M Simonelli","year":"2016","unstructured":"Simonelli M, Di Tommaso L, Baretti M, Santoro A. Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma. Immunotherapy 2016;8:1363\u20131369","journal-title":"Immunotherapy"},{"key":"9921_CR40","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41395-018-0058-z","volume":"113","author":"PA Schmeltzer","year":"2018","unstructured":"Schmeltzer PA, Russo MW. Clinical narrative: autoimmune hepatitis. Am J Gastroenterol 2018;113:951\u2013958","journal-title":"Am J Gastroenterol"},{"key":"9921_CR41","doi-asserted-by":"publisher","first-page":"e000268","DOI":"10.1136\/esmoopen-2017-000268","volume":"2","author":"GJ Doherty","year":"2017","unstructured":"Doherty GJ, Duckworth AM, Davies SE, Mells GF, Brais R, Harden SV, et al. Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. ESMO Open 2017;2:e000268","journal-title":"ESMO Open"},{"key":"9921_CR42","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","volume":"35","author":"H Kawakami","year":"2017","unstructured":"Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H, Takeda M, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Investig New Drugs 2017;35:529\u2013536","journal-title":"Investig New Drugs"},{"key":"9921_CR43","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.jhep.2018.08.014","volume":"69","author":"L Parlati","year":"2018","unstructured":"Parlati L, Vallet-Pichard A, Batista R, Hernvann A, Sogni P, Pol S, et al. Incidence of grade 3\u20134 liver injury under immune checkpoints inhibitors: a retrospective study. J Hepatol 2018;69:1396\u20131397","journal-title":"J Hepatol"},{"key":"9921_CR44","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","volume":"39","author":"M Johncilla","year":"2015","unstructured":"Johncilla M, Misdraji J, Pratt DS, Agoston AT, Lauwers GY, Srivastava A, et al. Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol 2015;39:1075\u20131084","journal-title":"Am J Surg Pathol"},{"key":"9921_CR45","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/PAS.0000000000000759","volume":"41","author":"J Everett","year":"2017","unstructured":"Everett J, Srivastava A, Misdraji J. Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis. Am J Surg Pathol 2017;41:134\u2013137","journal-title":"Am J Surg Pathol"},{"key":"9921_CR46","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/hepr.13191","volume":"48","author":"N Nishida","year":"2018","unstructured":"Nishida N, Kudo M. Immune checkpoint blockade for the treatment of human hepatocellular carcinoma. Hepatol Res 2018;48:622\u2013634","journal-title":"Hepatol Res"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-018-9921-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-018-9921-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-018-9921-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:20:26Z","timestamp":1659097226000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-018-9921-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5,1]]}},"alternative-id":["9921"],"URL":"https:\/\/doi.org\/10.1007\/s12072-018-9921-7","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,3]]},"assertion":[{"value":"12 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Naoshi Nishida and Masatoshi Kudo have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is not a research paper involving human participants and\/or animals; informed consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}